A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta

Neural Regeneration Research

Volumn 8, Issue 27, 2013, Pages 2581-2590

  Guo, Wan Shu ^a   Sha, Sha ^a   Jiang, Tong Zi ^b   Xing, Xiao Na ^a   Cao, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang First People's Hospital   (China)

Author keywords

Active immunotherapy; Alzheimer's disease; Amyloid ; C3d p28 molecular adjuvant; C57BL 6J mice; DNA vaccine; Grants supported paper; Neural regeneration; Neuroregeneration; Passive immunotherapy; Th2 immune response

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; COMPLEMENT COMPONENT C3D; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; PROTEIN P28; CYTOKINE; DNA FRAGMENT; MONOCLONAL ANTIBODY; P(A BETA 3 10)10 C3D P28.3 VACCINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MOUSE; MUSCLE ATROPHY; NONHUMAN; RECOMBINANT PLASMID; SEQUENCE ANALYSIS; SPECTROPHOTOMETRY; SPLEEN CELL; T LYMPHOCYTE; TH2 CELL; TRANSGENIC MOUSE; WESTERN BLOTTING; AGAR GEL ELECTROPHORESIS; ANTIBODY TITER; BLOOD SAMPLING; C57BL MOUSE; CELLULAR IMMUNITY; HEK293 CELL LINE; MTT ASSAY; SPECTROPHOTOMETER;

EID: 84889008216     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.27.010     Document Type: Article

References (46)

1. Alzheimer's Disease International. 2012. World Alzheimer Report 2011. http://www.alz.co.uk/research/world-report-2011 (accessed May 31, 2012).
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzhei-mer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
3. Jin M, Shepardson N, Yang T, et al. Soluble amyloid be-ta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degenera-tion. Proc Natl Acad Sci U S A. 2011;108(14):5819-5824.
4. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010;277(6): 1348-1358.
5. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.
6. Morgan D, Diamond DM, Gottschoall PE, et al. A beta peptide vaccination prevents memory loss in an animal-model of Alzheimer's disease. Nature. 2000; 408(6815):982-985.
7. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and pla-ques in a model of Alzheimer's disease. Nature. 2000; 408(6815):979-982.
8. Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med. 2011;269(1):54-63.
9. Lemere CA, Masliah E. Can Alzheimer disease be pre-vented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6(2):108-119.
10. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46-54.
11. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-1562.
12. Wisniewski T, Frangione B. Immunological and anti-cha-perone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005;15(1):72-77.
13. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216-223.
14. Cui LL, Huang XM, Wang JP, et al. Specific and efficient anti-Aβ42 antibodies induced by sixteen tandem repeats of Aβ9. J Neuroimmunol. 2010;227(1-2):18-25.
15. Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alz-heimer disease. J Neuroimmunol. 2013;254(1-2):63-68.
16. Tokita Y, Kaji K, Lu J, et al. Assessment of non-viral amy-loid-β DNA vaccines on amyloid-β reduction and safety in rhesus monkeys. J Alzheimers Dis. 2010;22(4):1351-1361.
17. Ghochikyan A, Davtyan H, Petrushina I, et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother. in press.
18. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant dependent modulation of Th1 and Th2 responses to im-munization with beta-amyloid. Int Immunol. 2003;15(4): 505-514.
19. DaSilva KA, Brown ME, McLaurin J. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vac-cine. 2009;27(9):1365-1376.
20. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and pa-tients with Alzheimer disease. J Clin Invest. 2003;112(3): 415-422.
21. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fi-brillogenesis. Nat Med. 2002;8(11):1263-1269.
22. Frenkel D, Kariv N, Solomon B. Generation of au-to-antibodies towards Alzheimer's disease vaccination. Vaccine. 2001;19(17-19):2615-2619.
23. Harigaya Y, Saido TC, Eckman CB, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun. 2000; 276(2):422-427.
24. Kou J, Kim HD, Jin J, et al. Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccina-tion-induced behavioral alterations. Brain Res. 2010;1356: 102-111.
25. Lambracht-Washington D, Qu BX, Fu M, et al. DNA be-ta-amyloid(1-42) trimer immunization for Alzheimer dis-ease in a wildtype mouse model. JAMA. 2009;302(16): 1796-1802.
26. Toapanta FR, Ross TM. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res. 2006;36(1-3):197-210.
27. Dempsey PW, Allison ME, Akkaraju S, et al. C3d of com-plement as a molecular adjuvant: bridging innate and acquired immunity. Science.1996;271(5274):348-350.
28. Movsesyan N, Mkrtichyan M, Petrushina I, et al. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and pola-rizes the immune response towards a Th2 phenotype. J Neuroimmunol. 2008;205(1-2):57-63.
29. Lambris JD, Ganu VS, Hirani S, et al. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A.1985;82(12):4235-4239.
30. Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol. 2006;586:249-264.
31. Dunn MD, Rossi SL, Carter DM, et al. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J. 2010;7:95.
32. Wang LX, Xu W, Guan QD, et al. Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization. World J Gastroenterol. 2004;10(14):2072-2077.
33. Zhang D, Xia Q, Wu J, et al. Construction and immuno-genicity of DNA vaccines encoding fusion protein of mu-rine complement C3d-p28 and GP5 gene of porcine re-productive and respiratory syndrome virus. Vaccine. 2011;29(4):629-635.
34. Bergmann-Leitner ES, Duncan EH, Leitner WW, et al. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protec-tion against Plasmodium berghei. Vaccine. 2007;25(45): 7732-7736.
35. Okura Y, Miyakoshi A, Kohyama K, et al. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A. 2006;103(25):9619-9624.
36. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for pro-tection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100(4):2023-2028.
37. Chauhan NB, Siegel GJ. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci Lett. 2005;375(3):143-147.
38. Maier M, Seabrook TJ, Lemere CA. Modulation of the humoral and cellular immune response in Abeta immu-notherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine. 2005;23(44):5149-5159.
39. Kim HD, Tahara K, Maxwell JA, et al. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Ab-eta1-6 up regulates IL-10 expression and reduces amy-loid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med. 2007;9(2):88-98.
40. Zhang YW, Thompson R, Zhang H, et al. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3.
41. Movsesyan N, Ghochikyan A, Mkrtichyan M, et al. Re-ducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strat-egy. PLoS One. 2008;3(5):e2124.
42. Shi JQ, Chen J, Wang BR, et al. Short amyloid-beta im-munogens show strong immunogenicity and avoid stimu-lating pro-inflammatory pathways in bone marrow-derived dendritic cells from C57BL/6J mice in vitro. Peptides. 2011;32(8):1617-1625.
43. Boche D, Denham N, Holmes C, et al. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010;120(3):369-384.
44. Fisher Y, Nemirovsky A, Baron R, et al. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One. 2010;5(5):e10830.
45. Zou J, Yao Z, Zhang G, et al. Vaccination of Alzheimer's model mice with adenovirus vector containing quadriva-lent foldable Abeta(1-15) reduces Abeta burden and be-havioral impairment without Abeta specific T cell response. J Neurol Sci. 2008;272(1-2):87-98.
46. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.